Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Get Thin MD vs Wisp

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.9

Get Thin MD

Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available
★★★★4

Starting at $169/mo

CompoundedSemaglutideTirzepatideBrand
Visit Get Thin MD
7.0

Wisp

Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested
★★★3.5

Starting at $225/mo

Brand WegovyBrand ZepboundBrand SaxendaCompounded Sublingual Semaglutide
Visit Wisp

Side-by-Side Comparison

FeatureGet Thin MDWisp
Overall Score7.9/107.0/10
Starting Price$169/mo$225/mo
Editorial Rating4 ★ /53.5 ★ /5
Features7 features6 features
States Available00
Compounded✓ Yes✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Get Thin MD

Pros

  • 3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
  • Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
  • Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
  • Nationwide availability with async evaluation — no in-person visit required
  • Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
  • Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."

Cons

  • Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
  • Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
  • State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
  • Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
  • Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix

Wisp

Pros

  • Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
  • LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
  • Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing

Cons

  • EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
  • Pharmacy partners not publicly named
  • States served list not publicly enumerated

Our Verdict

Winner: Get Thin MDScore: 7.9/10

Get Thin MD edges out Wisp with a higher overall score of 7.9/10 and is particularly strong for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.